The next live webinar to be done through the partnership of GRACE and LUNGevity Foundation will be on the timely subject of using molecular features of a resected non-small cell lung cancer in order to better understand the probability of the cancer recurring. This will be on November 14th, 7 PM Eastern/4 PM Pacific, and will hope to answer the question, "Could these molecular features improve upon current staging efforts to help us refine our recommendations of which patients should receive post-operative chemotherapy in order to reduce the chance of recurrence?"

To help us answer that question, we'll be joined by Dr. Johannes Kratz, surgeon at Massachusetts General Hospital in Boston, who participated in important research while previously at the University of California in San Francisco on a molecular profile that can be performed on archived tissue (stored in wax after completion of the surgery) and has demonstrated an ability to discriminate between patients with a better or worse prognosis after surgery. This research was published in the prestigious journal The Lancet (with Dr. Kratz as lead author), was highlighted in one of my posts at the beginning of this year as an exciting new development, and this testing platform has recently become commercially available.

Dr. Kratz will review various efforts pursued to use tumor biology to refine treatment recommendations in patients with early stage NSCLC, including the benefits and limitations of different strategies. He will discuss ongoing research and current standards of care in this clinical setting.

Following his talk for about 40-45 minutes, the remainder of the hour-long program will be available for questions from our live audience. As always, we'll turn his presentation into a series of podcasts, but we hope to have you join us for this timely, interesting topic that could lead to better treatment for potentially curable patients with lung cancer. 

Registration is through this link and, as always, is free.  We hope to have you join us!